541 656
active surveillance for localized prostate cancer. Eur Urol 2015;67:
993–1005
.
[9]
van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297–305.
[10]
Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health 2012;15:812–20.[11]
Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: The National Prostate Cancer Register (NPCR) of Sweden and Prostate Cancer Data Base Sweden (PCBaSe) 2.0. Int J Epidemiol 2013;42: 956–67.[12]
Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base — a refined prostate cancer trajecto- ry. Int J Epidemiol 2016;45:73–82.[13]
Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol 2013;190:1742–9.[14]
Bratt O, Carlsson S, Holmberg E, et al. The Study of Active Monitor- ing in Sweden (SAMS): a randomized study comparing two differ- ent follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol 2013;47:347–55.[15]
White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30: 377–99.[16]
Kalbfleisch J, Prentice R. The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons; 2002.[17]
Bongers ML, De Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Coupe VM. Multistate statistical modeling: a tool to build a lung cancer microsimulation model that includes parameter uncertainty and patient heterogeneity. Med Decis Making 2016;36:86–100.
[18]
Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices — overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 2012;32:667–77.
[19]
Lindhagen L, Van Hemelrijck M, Robinson D, Stattin P, Garmo H. How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Med Informat Decis Making 2015;15:96.
[20]
Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272–7.[21]
Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol 2016;13:151–67.
[22]
Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2016;34:2182–90.
[23]
Chamie K, Williams SB, Hershman DL, Wright JD, Nguyen PL, Hu JC. Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer 2015;121:4150–7.
[24]
Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J Urol 2016; 196:721–6.
[25]
Dowrick AS, Wootten AC, Howard N, Peters JS, Murphy DG. A pro- spective study of the short-term quality-of-life outcomes of patients undergoing transperineal prostate biopsy. BJU Int 2016;118:60–7.
[26]
Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.
[27]
van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in pros- tate cancer: the PRIAS study. Eur Urol 2007;52:1560–3.
[28]
Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2015;67:627–36.
[29]
Aly M, Dyrdak R, Nordstrom T, et al. Rapid increase in multidrug- resistant enteric bacilli blood stream infection after prostate biopsy — a 10-year population-based cohort study. Prostate 2015;75:947–56.
[30]
Henderson DR, de Souza NM, Thomas K, et al. Nine-year follow-up for a study of diffusion-weighted magnetic resonance imaging in a prospective prostate cancer active surveillance cohort. Eur Urol 2016;69:1028–33.[31]
Felker ER, Wu J, Natarajan S, et al. Serial magnetic resonance imaging in active surveillance of prostate cancer: incremental value. J Urol 2016;195:1421–7.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 3 4 – 5 4 1
541